Rol' infliksimaba v lechenii ankiloziruyushchego spondilita
- Authors: Bochkova A.G1
-
Affiliations:
- ГУ Институт ревматологии РАМН, Москва
- Issue: Vol 7, No 8 (2005)
- Pages: 638-642
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/91971
- ID: 91971
Cite item
Full Text
Abstract
Контролируемые исследования при анкилозирующем спондилите (АС) сульфасалазина, метотрексата, а по предварительным данным и лефлуномида не выявили безусловного превосходства над плацебо при аксиальной форме заболевания. Эти препараты недостаточно “надежны” и в случае поражения при АС периферических суставов [1, 2]. У большинства больных АС основную роль в лечении продолжают играть (наряду с физическими упражнениями, физиотерапией и образованием пациентов) нестероидные противовоспалительные препараты (НПВП). Поэтому появление первых сообщений об эффективности нового класса препаратов, ингибиторов фактора некроза опухолей-a (ФНО-a) при ревматоидном артрите было встречено с большим воодушевлением, и вскоре эти "биологические" препараты стали испытываться и у больных АС. В данном обзоре приводятся сведения только об одном из этих препаратов – инфликсимабе.
Full Text
##article.viewOnOriginalSite##About the authors
A. G Bochkova
ГУ Институт ревматологии РАМН, МоскваЛаборатория серонегативных спондилоартритов и остеоартроза
References
- Chen J, Lui C. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2004; 3: CD004524.
- Chen J, Lui C. Sulfasalasin for ankylosing spondylitis. Cochrane Database Syst Rev 2005, Apr 18; 2: CD004800.
- van den Bosch F, Kruithof E, Baeten D et al. Effects of loading dose regimen of three infusions of chimeric antibody to tumor necrosis factor (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59: 428–33.
- Brandt J, Haibel H, Cornely D et al. Successful treatment of active ankylosing spondylitis with the antitumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346–52.
- van der Bosch F, Kruthof E, Baeten D et al. Safety and efficacy of a retreatment regimen of 10mg/kg infliximab every 14 weeks in patients with active spondyloarthropathy. Arthritis Rheum 2002; 46 (9 Suppl): S430.
- Breban M, Vignon E, Claudepierre P et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six - month open - label study. Rheumatology (Oxford) 2002; 41: 1280–5.
- Temekonidis T.I, Alamanos Y, Nikas S.N et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003; 62 (12): 1218–20.
- Maksymowych W, Jhangri G, Lambert R et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002; 29: 959–65.
- Braun J, Brandt J, Listing J et al. Long - term efficacy and safety of infliximab in the treatment of ankylosing spondilitis: an open, observational, extension study of a three - month, randomized, placebo - controlled trial. Arthritis Rheum 2003; 48: 2224–33.
- Braun J, Brandt J, Listing J et al. Two year maintenance of efficacy and safety on infliximab in the treatment of ankylosing spondilitis. Ann Rheum Dis 2005; 64: 229–34.
- Baraliakos X, Brandt J, Listing J et al. Clinical response to long - term therapy with infliximab in patients with ankylosing spondylitis - results after 3 years [abstract]. Presented at: Annual European Congress of Rheumatology; Berlin Germany; June 9–12, 2004. Abstract SAT0084.
- van der Bosch F, Kruthof E, Baeten D et al. Randomized double - blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloartghropathy. Arthritis Rheum 2002; 46: 755–65.
- van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondilitis. Results of a randomized, placebo controlled trial (ASSERT). Arthritis Rhum 2005; 52: 582–91.
- Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187–93.
- Marzo-Ortega H, Mc Gonagle D, Jarrett S et al. Infliximab in combination with methotrexate in active ankylosing spondylitis. A clinical and imaging study. Ann Rheum Dis 2005 May 26; [Epub ahead of print].
- Lipsky P.E, van der Heijde, St. Clair E.W et al. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594–602.
- Rudwaleit M, Listing J, Brandt J et al. Prediction on a major clinical response (BASDAI 50) to TNF-ablokers in ankylosing spondilitis? Ann Rheum Dis 2004; 63: 665–70.
- Rudwaleit M, Siegert S, Yin Z et al. Low T cell production of TNF-a and INF-g in ankylosing spondylitis its relation to HLA-B27 and influense of the TNF-308 gene polymorphism. Ann Rheum Dis 2001; 60: 36–42.
- Gonsales S, Torre-Alonso J.C, Martines-Borra J et al. TNF-238A promoter polymorphism contributes to susceptibility to ankylosing spondylitis in HLA-B27 negative patients. J Rheumatol 2001; 28: 1288–93.
- Braun J, Baraliakos X, Golder W et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003; 48: 1126–36.
- Kruithof, D Baeten, F Van den Bosch, H Mielants, E M Veys and F De Keyser Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy Ann Rheum Dis; April 2005 (Volume 64, Number 4).
- Xenofon Baraliakos, Joachim Listing, Martin Rudwaleit et al. Radiographic progression in patients with ankylosing spondylitis after two years of treatment with the tumor necrosis factor-З antibody infliximab. Ann Rheum Dis Apr 2005; 64 (4).
- Brandt J, Listing J, Krause A et al. Socioeconomic consequences for patients with active ankylosing spondylitis treated for two years with infliximab in a clinical trial [abstract]. Ann Rheum Dis 2003; 62 (Suppl. 1). Abstract FRI0201.
- Румянцева О.А, Кузин А.В, Бунчук Н.В. Применение ремикейда при анкилозирующем спондилоартрите (предварительные результаты). Клин. фармакол. и тер. 2004; 13 (1): 89–93.
- Бунчук Н.В., Румянцева О.А, Бочкова А.Г. и др. Анкилозирующий спондилит: международный и отечественный опыт применения инфликсимаба. V Российский съезд ревматологов, Казань, май 2005 г., симпозиум "Антицитокиновая терапия при ревматических заболеваниях".
- Hyrich K.L, Silman A.J, Watson K.D, D.P.M Symmons. Anti - tumor necrosis factor a therapy in rheumatoid arthritis: an update on safety. Ann Rheumatic Disease 2004; 63 (12): 1538–43.
- Braun J, Pham T, Sieper J et al. International ASAS consensus statement for the use of anti - tumor necrosis factor agents in patients with ankylosing spondilitis. Ann Rheum Dis 2003; 62: 817–24.
- Carmona L, Gomes-Reino J.J, Rodriguez-Valverde V et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonist. Arthritis Rheum 2005, Jun 2; 52 (6): 1766–72.
- Van der Linden et al. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361–8.